BR112015010477A2 - combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas - Google Patents

combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas

Info

Publication number
BR112015010477A2
BR112015010477A2 BR112015010477A BR112015010477A BR112015010477A2 BR 112015010477 A2 BR112015010477 A2 BR 112015010477A2 BR 112015010477 A BR112015010477 A BR 112015010477A BR 112015010477 A BR112015010477 A BR 112015010477A BR 112015010477 A2 BR112015010477 A2 BR 112015010477A2
Authority
BR
Brazil
Prior art keywords
inhibitor
treatment
histone deacetylase
proliferative diseases
pharmaceutical combination
Prior art date
Application number
BR112015010477A
Other languages
English (en)
Portuguese (pt)
Inventor
Mijatov Branka
Jin Lei
Hersey Peter
John GALLAGHER Stuart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015010477A2 publication Critical patent/BR112015010477A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015010477A 2012-11-08 2013-11-08 combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas BR112015010477A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723925P 2012-11-08 2012-11-08
PCT/EP2013/073452 WO2014072493A1 (en) 2012-11-08 2013-11-08 Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BR112015010477A2 true BR112015010477A2 (pt) 2017-07-11

Family

ID=49552384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010477A BR112015010477A2 (pt) 2012-11-08 2013-11-08 combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas

Country Status (11)

Country Link
US (1) US20150283136A1 (enExample)
EP (1) EP2916834A1 (enExample)
JP (1) JP2015536964A (enExample)
CN (1) CN104994850A (enExample)
AU (1) AU2013343425A1 (enExample)
BR (1) BR112015010477A2 (enExample)
CA (1) CA2890663A1 (enExample)
HK (1) HK1214765A1 (enExample)
RU (1) RU2015121367A (enExample)
UA (1) UA115151C2 (enExample)
WO (1) WO2014072493A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
RS58048B1 (sr) 2011-11-23 2019-02-28 Array Biopharma Inc Farmaceutske formulacije
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017019664A1 (en) * 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US10864179B2 (en) * 2015-10-01 2020-12-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3571200B8 (en) 2017-01-17 2022-08-03 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
DK2688572T3 (en) * 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
NZ618367A (en) * 2011-06-14 2016-01-29 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Also Published As

Publication number Publication date
HK1214765A1 (zh) 2016-08-05
JP2015536964A (ja) 2015-12-24
CN104994850A (zh) 2015-10-21
WO2014072493A1 (en) 2014-05-15
EP2916834A1 (en) 2015-09-16
US20150283136A1 (en) 2015-10-08
AU2013343425A1 (en) 2015-06-11
UA115151C2 (uk) 2017-09-25
RU2015121367A (ru) 2017-01-10
CA2890663A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
IN2015DN00376A (enExample)
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
IN2015DN00450A (enExample)
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112014008036A2 (pt) tratamento de rinite
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
EA201490417A1 (ru) Новые легкоразрушающиеся ингибиторы pde 4
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112014028951A2 (pt) peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
BRPI1013363A8 (pt) Peptídeo para o tratamento profilático ou terapêutico de tumores da pele em estágios iniciais
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2539 DE 03-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.